
51 - 200 employees
Founded 2004
🧬 Biotechnology
💊 Pharmaceuticals
💰 $75M Post IPO equity on 2024-02
Biotechnology • Pharmaceuticals
Liquidia is a biopharmaceutical company focused on developing inhaled therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company leverages its proprietary PRINT® particle engineering technology to create proprietary formulations and delivery methods aimed at improving efficacy, tolerability, and convenience of inhaled medicines; its pipeline includes inhaled treprostinil (commercial product) and clinical-stage candidates such as L606. Liquidia emphasizes patient support, clinical development, and advancing therapies for improved respiratory outcomes.
Selected: 🇺🇸 United States – Remote USA.
Selected: 🆕 Date Added.
🕒 September 3
Legal Operations Manager optimizing legal technology, contracts, budgets, and risk processes. Supporting Liquidia, a biopharmaceutical company developing pulmonary hypertension therapies.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
🔴 Lead
🧑💼 Attorney / Lawyer
👻 Ghost score 10%
🕒 September 3
Senior Manager guiding global regulatory strategy and submissions for Liquidia’s pulmonary hypertension therapies. Supporting drug-device combination products through clinical development and commercialization.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
🚔 Compliance
👻 Ghost score 10%
🕒 August 22
Senior Director leading regulatory and clinical medical writing for Liquidia, a company developing pulmonary arterial hypertension therapies. Guiding global submissions, health authority interactions, and cross-functional document strategy.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟠 Senior
👨⚕️ Medical Director
👻 Ghost score 10%
🕒 July 27
Director of Commercial Strategy leading product planning and growth at Liquidia, focused on pulmonary hypertension treatment and commercialization strategies.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🔴 Lead
👔 Director
👻 Ghost score 22%
🕒 July 27
Field based Regional Key Account Director at Liquidia supporting launch of Yutrepia for PAH treatment. Collaborating with marketing, sales, and medical teams to drive strategic partnerships and KOL engagement.
🇺🇸 United States – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🔴 Lead
🧑💼 Account Executive
👻 Ghost score 22%
🕒 July 27
Sales professional managing territory accounts focusing on pulmonary hypertension treatments for Liquidia. Leveraging entrepreneurial mindset to grow sales within specific geographic areas.
🗽 New York – Remote
💰 $75M Post IPO equity on 2024-02
⏰ Full Time
🟡 Mid-level
🟠 Senior
💰 Account Manager
👻 Ghost score 22%